Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in DKK (TTM)232.26bn
  • Net income in DKK83.68bn
  • Incorporated1931
  • Employees63.37k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVO B:CPH since
announced
Transaction
value
Cardior Pharmaceuticals GmbHAnnounced25 Mar 202425 Mar 2024Announced-0.67%1.11bn
Catalent Inc-Manufacturing Sites Portfolio(3)Announced05 Feb 202405 Feb 2024Announced12.78%--
Elan Drug Technologies (DNU>16Sep2011 now 01781A)Announced14 Dec 202314 Dec 2023Announced31.18%92.42m
Embark Biotech ApSDeal completed29 Aug 202329 Aug 2023Deal completed36.32%16.22m
Inversago Pharma IncDeal completed10 Aug 202310 Aug 2023Deal completed39.51%1.08bn
Data delayed at least 15 minutes, as of Mar 27 2024 15:59 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.